Clinical use and pharmacological properties of selective COX-2 inhibitors

  title={Clinical use and pharmacological properties of selective COX-2 inhibitors},
  author={Shao-jun Shi and Ulrich Klotz},
  journal={European Journal of Clinical Pharmacology},
  • S. Shi, U. Klotz
  • Published 1 March 2008
  • Medicine
  • European Journal of Clinical Pharmacology
Selective COX-2 inhibitors (coxibs) are approved for the relief of acute pain and symptoms of chronic inflammatory conditions such as osteoarthritis (OA) and rheumatoid arthritis (RA). They have similar pharmacological properties but a slightly improved gastrointestinal (GI) safety profile if compared to traditional nonsteroidal anti-inflammatory drugs (tNSAIDs). However, long-term use of coxibs can be associated with an increased risk for cardiovascular (CV) adverse events (AEs). For this… 

Selective cyclooxygenase-2 inhibitors in dentistry: limitations and adverse effects

The coxibs should be used in patients over 60 years, with a history of peptic ulcer or gastrointestinal bleeding, chronic users of corticosteroids and anticoagulants without concomitant cardiovascular risk, and in dentistry, where there is no major evidence of the benefits of using these drugs compared to traditional NSAIDs.

Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases.

The present review considers the most recently published literature concerning COX-2 inhibitors and the last developments concerning this therapeutic family by highlighting structure-activity relationships insights and mechanisms are presented.

Pharmacokinetics and pharmacodynamics of some NSAIDs in horses: A pharmacological, biochemical and forensic study

Investigation of the effects of the two coxib NSAIDs in six retired race horses found that both drugs have no adverse side effects in the horse and their metabolites are completely eliminated within 120 hours following oral administration.

Selective inhibition of cyclooxygenase-2: risks and benefits.

The mechanisms underlying the cardiovascular effects are discussed, pointing out the advantages and disadvantages of the selective or nonselective COX inhibitors.

Nonsteroidal Anti-Inflammatory Drugs and the Kidney

  • W. Hörl
  • Medicine, Biology
  • 2010
This review summarizes the present knowledge how traditional NSAIDs and selective COX-2 inhibitors may affect the kidney under various experimental and clinical conditions, and how these drugs may influence renal inflammation, water transport, sodium and potassium balance and how renal dysfunction or hypertension may result.

Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).

This manuscript highlights the structure-activity relationships which characterize the chemical scaffolds endowed with selective COX-2 inhibition and the role of COx-2 inhibitors in the pain phenomenon and cancer is discussed.

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

  • S. ShiU. Klotz
  • Medicine, Biology
    European Journal of Clinical Pharmacology
  • 2008
This update of pharmacokinetic, pharmacodynamic, and clinical data will provide the necessary guide by which to select between the various PPIs that differ—based on pharmacodynamic assessments—in their relative potencies.

Celecoxib in Cancer Therapy and Prevention - Review.

Both preclinical and clinical studies have demonstrated promising results of the role of celecoxib in the treatment and prevention of cancer - the best outcome was observed in colon, breast, prostate and head and neck cancers.

Celecoxib in the Treatment of Osteoarthritis

This review illustrates how best to consider selective COX-2 inhibitors role in the current treatment of pain associated with arthritis with an emphasis on osteoarthritis.

Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold.

Molecular docking studies using the catalytic site of COX-1 andCOX-2 provided complementary theoretical support for the obtained experimental biological structure–activity relationship data of three highly potent and selective fluorobenzyl-containing COx-2 inhibitors.



COX-2 inhibitors and the heart: are all coxibs the same?

The take home message for prescribing NSAIDs and those coxibs still on the market seems to be one of caution rather than contraindication, except in patients with significant cardiovascular risk factors.

Clinical pharmacology of novel selective COX-2 inhibitors.

Several randomized clinical studies suggest that the novel coxibs have comparable efficacy to nonselective NSAIDs in the treatment of osteoarthritis, rheumatoid arthritis and acute pain, but they share similar renal side-effects.

Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib

Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is the first specific inhibitor of cyclo-oxygenase-2 (COX-2) approved to treat patients with rheumatism and osteoarthritis. Preliminary data

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.

Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.

An updated overview on the functions of COX-2 in the cardiovascular system is provided addressing key issues that could help to understand why chronic COx-2 inhibition may have undesirable effects in patients at cardiovascular risk.

Pharmacodynamic of cyclooxygenase inhibitors in humans.

Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine

Concern is whether the reported cardiovascular effects of rofecoxib are a class effect applicable to all coxibs that were initially designed to reduce the gastric toxicity of nonselective COX inhibitors.

[Cardiovascular events: a class effect by COX-2 inhibitors].

Non-steroidal anti-inflamatories (NSAIDs) are widely used in the treatment of post-surgery pain, rheumatoid arthritis, and muscle-skeletal pain in different conditions and it is believed that COX-1 also plays a role in pathologic conditions such as inflammation.